IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Studies show that administration of interferon (IFN)-alpha causes a significant increase in depressive symptoms. The enzyme indoleamine 2,3-dioxygenase (IDO), which converts tryptophan (TRP) into kynurenine (KYN) and which is stimulated by proinflammatory cytokines, may be implicated in the development of IFN-alpha-induced depressive symptoms, first by decreasing the TRP availability to the brain and second by the induction of the KYN pathway resulting in the production of neurotoxic metabolites. Sixteen patients with chronic hepatitis C, free of psychiatric disorders and eligible for IFN-alpha treatment, were recruited. Depressive symptoms were measured using the Montgomery Asberg Depression Rating Scale (MADRS). Measurements of TRP, amino acids competing with TRP for entrance through the blood-brain barrier, KYN and kynurenic acid (KA), a neuroprotective metabolite, were performed using high-performance liquid chromatography. All assessments were carried out at baseline and 1, 2, 4, 8, 12 and 24 weeks after treatment was initiated. The MADRS score significantly increased during IFN-alpha treatment as did the KYN/TRP ratio, reflecting IDO activity, and the KYN/KA ratio, reflecting the neurotoxic challenge. The TRP/CAA (competing amino acids) ratio, reflecting TRP availability to the brain, did not significantly change during treatment. Total MADRS score was significantly associated over time with the KYN/KA ratio, but not with the TRP/CAA ratio. Although no support was found that IDO decreases TRP availability to the brain, this study does support a role for IDO activity in the pathophysiology of IFN-alpha-induced depressive symptoms, through its induction of neurotoxic KYN metabolites.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“cytokine-induced activation of the enzyme, indolamine 2,3 dioxygenase (IDO), which metabolizes tryptophan to kynurenine and quinolinic acid, is believed to contribute to reduced availability of serotonin.16,23,24”
From Cytokines and Glucocorticoid Receptor Signaling (2009) · cites this paper as [24]
In the citing paper
“Following IDO activation, both the reduced peripheral availability of tryptophan (putatively leading to reduced serotonin synthesis in the brain) and the production of neurotoxic tryptophan metabolites are considered essential steps in the pathophysiological processes.”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“3-hydroxykynurenine and quinolinic acid are NMDA receptor agonists, potentially neurotoxic and thus potentially contributing to depression”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“which converts tryptophan into kynurenine (KYN), a precursor of 3-hydroxykynurenine, a neurotoxic metabolite, and kynurenic acid, a neuroprotective metabolite”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“kynurenic acid is an N-methyl d-aspartate (NMDA) receptor antagonist, and is generally considered neuroprotective”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016
Hippocampal Volume Reduction in Major Depression
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.115 · Cited by 1,670
Glial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
Sheline, Y. I., Sanghavi, M., Mintun, M. A., & Gado, M. H. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05034.1999 · Cited by 1,382
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Untreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Research works printed but not linked: 2
- Maes M, Meltzer H . The serotonin hypothesis of major depression. In: Bloom F, Kupfer D, (eds) Psychopharmacology. Raven Press: New York, 1995 pp 933–944.
- Stockmeier CA, Mahajan G, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY et al. Neuronal and glial density is increased and neuronal soma size is decreased in the hippocampus in major depressive disorder (MDD). Biol Psychiatry 2003; 53S: 198.
Cited by
Items 101–200 of 445
Zhang, B., Wang, P., Hu, K., Li, L., Yu, X. L., Lu, Y., & Hong-sheng, C. (2019) · Molecules · doi:10.3390/molecules24112035 · Cited by 121
The possible role of the kynurenine pathway in adolescent depression with melancholic features
Gabbay, V., Klein, R. G., Katz, Y., Mendoza, S., Guttman, L. E., Alonso, C. M., Babb, J. S., Hirsch, G. S., & Liebes, L. (2010) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2010.02245.x · Cited by 115
The kynurenine pathway in major depression: What we know and where to next
Brown, S. J., Huang, X.-F., & Newell, K. A. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.05.018 · Cited by 113
Baranyi, A., Amouzadeh-Ghadikolai, O., von Lewinski, D., Rothenhäusler, H., Theokas, S., Robier, C., Mangge, H., Reicht, G., Hlade, P., & Meinitzer, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160542 · Cited by 127
“The clinical relevance of this competitive effect is not fully understood and controversially discussed [13].”
BackgroundLaugeray, A., Launay, J., Callebert, J., Surget, A., Belzung, C., & Barone, P. R. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.02.014 · Cited by 120
Parrott, J. M., Redus, L., & O’Connor, J. C. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0590-y · Cited by 112
“Interferon-α immunotherapy resulted in elevated serum kynurenine/tryptophan ratio, indicative of increased IDO activity, as well as increased cerebrospinal fluid (CSF) levels of kynurenine, KA, and QA [27, 28].”
BackgroundAnderson, G., Berk, M., & Maes, M. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12182 · Cited by 110
“IFNa-based treatment induces depressive symptoms in association with reduced plasma tryptophan, increased serum kynurenine, and increased kyn/tryptophan ratio, reflecting increased IDO activity (110, 111).”
BackgroundSelf-citationThe Metabolic Factor Kynurenic Acid of Kynurenine Pathway Predicts Major Depressive Disorder
Liu, H., Ding, L., Zhang, H., Mellor, D., Wu, H., Zhao, D., Wu, C., Lin, Z., Yuan, J., & Peng, D. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00552 · Cited by 104
Filho, A. J. M. C., Lima, C. N. D. C., Vasconcelos, S. M. M., de Lucena, D. F., Maes, M. H. J., & Macêdo, D. S. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.035 · Cited by 116
“Bonaccorso et al. (2002) and Wichers et al. (2005) demonstrated that the onset of depressive symptoms during IFN-α-based immunotherapy was positively associated with the KYN/TRY and KYN/KYNA ratios.”
BackgroundInfluentialSelf-citationTryptophan depletion in depressed patients occurs independent of kynurenine pathway activation
Hughes, M. M., Carballedo, A., McLoughlin, D. M., Amico, F., Harkin, A., Frodl, T., & Connor, T. J. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.05.010 · Cited by 114
The role of the kynurenine metabolism in major depression
Myint, A.-M., Schwarz, M., & Müller, N. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0741-3 · Cited by 126
Gibney, S. M., Fagan, E. M., Waldron, A.-M., O‘Byrne, J., Connor, T. J., & Harkin, A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001673 · Cited by 101
“Also recent clinical studies argue against IDO-mediated depletion of 5-HT synthesis in depressed patients (Wichers et al., 2005; Myint et al., 2007) and it has been suggested that the action of kynurenine metabolites on the glutamatergic system may be involved in producing depressive symptoms…”
BackgroundKaru, N., McKercher, C., Nichols, D. S., Davies, N. W., Shellie, R. A., Hilder, E. F., & Jose, M. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0387-3 · Cited by 116
“The second direction is the neuroactivity of the kynurenine pathway metabolites (kynurenines) [2, 4, 26, 27], which can originate in”
BackgroundMoaddel, R., Fabbri, E., Khadeer, M. A., Carlson, O. D., Gonzalez-Freire, M., Zhang, P., Semba, R. D., & Ferrucci, L. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw046 · Cited by 99
Quak, J., Doornbos, B., Roest, A. M., Duivis, H. E., Vogelzangs, N., Nolen, W. A., Penninx, B. W. J. H., Kema, I. P., & de Jonge, P. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.03.013 · Cited by 98
“a therapy (Capuron et al., 2003; Wichers et al., 2005).”
BackgroundFranscina Pinto, E., & Andrade, C. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160106155129 · Cited by 98
“These neurochemical and neurohistological changes predispose to depression [28, 44, 47-49].”
BackgroundPain, O., Dudbridge, F., Cardno, A. G., Freeman, D., Lu, Y., Lundstrom, S., Lichtenstein, P., & Ronald, A. (2018) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32630 · Cited by 97
Biomarkers of psychiatric diseases: Current status and future prospects
Kalia, M., & Silva, J. C. E. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.026 · Cited by 123
Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorders
Savitz, J. B. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_12 · Cited by 108
Clark, S. M., Pocivavsek, A., Nicholson, J. D., Notarangelo, F. M., Langenberg, P., McMahon, R. P., Kleinman, J. E., Hyde, T. M., Stiller, J., Postolache, T. T., et al. (2016) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.150226 · Cited by 94
Maes, M. H. J. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.023 · Cited by 117
Self-citationMüller, N., Myint, A.-M., & Schwarz, M. J. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.3/nmueller · Cited by 93
“A recent study showed that depressive symptoms are related to an high ratio of KYN/KYNA in depression.(114) P h a r m a c o l o g i c a l a s p e c t s”
Serum kynurenic acid is reduced in affective psychosis
Wurfel, B. E., Drevets, W. C., Bliss, S. A., McMillin, J. R., Suzuki, H., Ford, B. N., Morris, H. M., Teague, T. K., Dantzer, R., & Savitz, J. B. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.88 · Cited by 92
Depression, fatigue and neurocognitive deficits in chronic hepatitis C
Yeoh, S. W., Holmes, A., Saling, M. M., Everall, I., & Nicoll, A. (2018) · Hepatology International · doi:10.1007/s12072-018-9879-5 · Cited by 100
Type I interferons induce autophagy in certain human cancer cell lines
Schmeisser, H., Fey, S. B., Horowitz, J., Fischer, E. R., Balinsky, C. A., Miyake, K., Bekisz, J., Snow, A. L., & Zoon, K. C. (2013) · Autophagy · doi:10.4161/auto.23921 · Cited by 90
Maes, M. H. J., Gałecki, P., Verkerk, R. M., & Rief, W. (2011) · PubMed · Cited by 100
Self-citationMaes, M. H. J., & Rief, W. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2011.09.029 · Cited by 105
“The development of depressive symptoms during IFNα-based immunotherapy is strongly associated with the KY/TRP and the KY/KA ratio, and lowered levels of tryptophan (Maes et al., 2001; Bonaccorso et al., 2002; Wichers et al., 2005; Maes, 2011; Raison et al., 2010).”
BackgroundSelf-citationThe microbiota-gut-brain axis: Focus on the fundamental communication pathways
(2020) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2020.08.012 · Cited by 88
Psychiatric and Substance Use Disorders in Individuals with Hepatitis C: Epidemiology and Management
Loftis, J. M., Matthews, A. M., & Hauser, P. (2006) · Drugs · doi:10.2165/00003495-200666020-00003 · Cited by 86
Lipidomics in the study of lipid metabolism: Current perspectives in the omic sciences
Rolim, A. E. H., Henrique-Araújo, R., Ferraz, E. G., Dultra, F. K. A. A., & Fernandez, L. G. (2014) · Gene · doi:10.1016/j.gene.2014.10.039 · Cited by 97
“Lipid abnormalities and the increment of immuneresponse and inflammation activation, may also contribute to the pathogenesis of mood disorders, in part due to the modulation in the metabolism of neurotransmitter systems and neurotoxic metabolites (Wichers et al., 2005).”
Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis
Georgin‐Lavialle, S., Moura, D. S., Salvador, A., Chauvet‐Gélinier, J., Launay, J., Damaj, G. L., Côté, F., Soucie, E. L., Chandesris, M., Barète, S., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.216 · Cited by 96
Smith, A. K., Simon, J. S., Gustafson, E. L., Noviello, S., Cubells, J. F., Epstein, M. P., Devlin, D. J., Qiu, P., Albrecht, J. K., Brass, C. A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.67 · Cited by 84
Anderson, G., Maes, M. H. J., & Berk, M. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.07.016 · Cited by 100
“Importantly, it is the increase in neuromdodulatory TRYCATs that is crucial to the induction of depression, and not simply a decrease in serotonin (Wichers and Maes, 2002, 2004; Wichers et al., 2005, 2007).”
BackgroundSelf-citationWichers, M., Kenis, G., Leue, C., Koek, G. H., Robaeys, G., & Maes, M. H. J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.024 · Cited by 92
Self-citationDey, A., & Hankey Giblin, P. A. (2018) · Pharmaceuticals · doi:10.3390/ph11030064 · Cited by 80
Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update
Sockalingam, S., Links, P. S., & Abbey, S. E. (2011) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2010.01393.x · Cited by 79
Cerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a Unique Metabolic Profile
Kaddurah-Daouk, R., Yuan, P., Boyle, S. H., Matson, W., Wang, Z., Zeng, Z. B., Zhu, H., Dougherty, G. G., Yao, J. K., Chen, G., et al. (2012) · Scientific Reports · doi:10.1038/srep00667 · Cited by 76
The Kynurenine Pathway in Traumatic Brain Injury: Implications for Psychiatric Outcomes
Meier, T. B., & Savitz, J. B. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.021 · Cited by 83
Glia in the cytokine-mediated onset of depression: fine tuning the immune response
Jo, W. K., Zhang, Y., Emrich, H. M., & Dietrich, D. E. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00268 · Cited by 77
“Moreover, studies evaluating the KYN pathway in the periphery have reported an increased KYN/KA ratio associated with depressive symptoms in individuals with HCV treated with IFN-α, and a reduced KA/QUIN ratio in MDD patients compared with controls (Wichers et al., 2005; Savitz et al., 2015).”
ResultInflammation and depression: Is there a causal connection with dementia?
E.Leonard, B., & Myint, A. (2006) · Neurotoxicity Research · doi:10.1007/bf03033243 · Cited by 76
“In these patients, it has been shown that the blood kynurenine concentration was reduced, thereby suggesting that the neurodegenerative metabolites were increased (Wichers et al., 2005).”
BackgroundSleep disturbance and kynurenine metabolism in depression
Cho, H. J., Savitz, J. B., Dantzer, R., Teague, T. K., Drevets, W. C., & Irwin, M. R. (2017) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.05.016 · Cited by 81
“In this study, KYN/TRP, a measure of IDO activity, was not significantly different across the never depressed, previously depressed, and currently depressed groups.”
BackgroundInfluentialHochstrasser, T., Ullrich, C., Sperner‐Unterweger, B., & Humpel, C. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.03.070 · Cited by 89
“In contrast, kynurenic acid acts as an antagonist of NMDA receptors and can be considered as neuroprotective (Wichers et al., 2005).”
Tryptophan Metabolism and Immunogenetics in Major Depression: A Role for Interferon-γ Gene
Myint, A. M., Bondy, B., Baghai, T. C., Eser, D., Nothdurfter, C., Schüle, C., Zill, P., Müller, N., Rupprecht, R., & Schwarz, M. J. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.04.003 · Cited by 74
“Enhanced formation of kynurenine from tryptophan, indicated by kynurenine/tryptophan ratio which indirectly indicates the IDO activity, was also observed in interferon-a treated patients who developed depression (Wichers et al., 2005) and in medication naïve patients with major depression compared to normal controls (…”
ResultSublette, M. E., & Postolache, T. T. (2012) · Psychosomatic Medicine · doi:10.1097/psy.0b013e318268de9f · Cited by 72
“symptoms is correlated with measures of IDO activity but not with measures of TRP availability to the brain (8) and that elevated cerebrospinal fluid KYN metabolites are not associated with depleted cerebrospinal fluid TRP (21).”
BackgroundTryptophan degradation in women with breast cancer: a pilot study
Lyon, D., Walter, J. M., Starkweather, A. R., Schubert, C. M., & McCain, N. L. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-156 · Cited by 79
“Secondly, breakdown of TRP through the KYN pathway leads to the production of a series of potentially neurotoxic metabolites, such as quinolinic acid [20].”
BackgroundKocki, T., Wnuk, S., Kloc, R., Kocki, J., Owe‐Larsson, B., & Urbańska, E. M. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0668-8 · Cited by 81
“Human studies demonstrated that IFN-a-evoked depressive symptoms correlate with a rise of serum kynurenine/KYNA ratio, probably reflecting deficit of endogenous neuroprotection (Wichers et al. 2005; Van Gool et al. 2008).”
BackgroundThe inflammatory underpinning of depression: An historical perspective
Yirmiya, R. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.08.048 · Cited by 87
“Building upon these findings, a subsequent study found increased densities of QUIN-labeled microglia, which are the main cell type that produces this kynurenine metabolite, in the ACC of depressed patients who died by suicide as opposed to those with bipolar disorder and controls (Steiner et al., 2011).”
InfluentialThe impact of electroconvulsive therapy on the tryptophan–kynurenine metabolic pathway
Gülöksüz, S., Arts, B. M. G., Walter, S., Drukker, M., Rodriguez, L., Myint, A.-M., Schwarz, M., Ponds, R., van Os, J., Kenis, G., et al. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.02.029 · Cited by 75
“However, in cases of interferon (IFN)-c and tumor necrosis factor (TNF)-a upregulation (such as is seen in inflammatory states, or with IFN-a treatment), the activity of IDO is induced, which in turn increases TRP turnover, and KYN accumulation (Myint, 2012b; Raison et al., 2010; Wichers et al., 2005).”
BackgroundMicroglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric Disorders
Lisboa, S. F. D. S., Gomes, F. V., Guimarães, F. S., & Campos, A. C. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00005 · Cited by 77
“Proinflammatory cytokines are proposed to activate IDO that, by interfering with tryptophan/ kynurenine metabolism, decreases serotonin levels and facilitates the production of quinolinic acid, an N-methyl-d-aspartate (NMDA) receptor agonist (40, 44).”
BackgroundNeuroimmune–endocrine crosstalk in schizophrenia and mood disorders
Müller, N., & Schwarz, M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.7.1017 · Cited by 77
Drago, A., Crisafulli, C., Sidoti, A., & Serretti, A. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.05.009 · Cited by 82
“It is relevant to stress before conclusion that neurotoxicity is considered as a possible relevant etiopathological mechanism of MDD (Wichers et al., 2005), this is why this pathway may be of relevance in unravelling the genetics of this disorder.”
BackgroundJohnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
The possible role of the kynurenine pathway in anhedonia in adolescents
Gabbay, V., Ely, B. A., Babb, J., & Liebes, L. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-011-0685-7 · Cited by 67
“Converging evidence indicates that peripheral induction of IDO plays a key role in initiating the KP cascade that leads to neurotoxicity and depressive symptoms (Wichers et al. 2005; Bonaccorso et al. 2002; Capuron et al. 2002, 2003a; Myint et al. 2007).”
BackgroundKynurenine Pathway in Autism Spectrum Disorders in Children
Bryn, V., Verkerk, R. M., Skjeldal, O. H., Saugstad, O. D., & Ormstad, H. (2017) · Neuropsychobiology · doi:10.1159/000488157 · Cited by 73
Self-citationSu, K.-P., Lai, H.-C., Peng, C.-Y., Su, W.-P., Chang, J. P.-C., & Pariante, C. M. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.04.032 · Cited by 68
Inflammation, stress and depression: An exploration of ketamine’s therapeutic profile
Johnston, J. N., Greenwald, M. S., Henter, I. D., Kraus, C., Mkrtchian, A., Clark, N. G., Park, L. T., Gold, P. W., Zarate, C. A., & Kadriu, B. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103518 · Cited by 80
Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives
Biernacki, T., Sandi, D., Bencsik, K., & Vécsei, L. (2020) · Cells · doi:10.3390/cells9061564 · Cited by 71
Laugeray, A., Launay, J., Callebert, J., Surget, A., Belzung, C., & Barone, P. R. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.008 · Cited by 72
Inflammation-Induced Catabolism of Tryptophan and Tyrosine in Acute Ischemic Stroke
Ormstad, H., Verkerk, R. M., Aass, H. C. D., Amthor, K.-F., & Sandvik, L. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-013-0097-2 · Cited by 73
“This is important, since KYN can exert detrimental effects, such as inducing depressive and anxiety symptoms, and additional excitotoxic and neurotoxic effects (Wichers et al. 2005; Maes and Rief 2012).”
BackgroundSelf-citationGabbay, V., Liebes, L., Katz, Y., Liu, S., Mendoza, S., Babb, J. S., Klein, R. G., & Gonen, O. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.09.015 · Cited by 64
“Activation of the KP has been hypothesized to contribute to glial loss and neuronal atrophy in specific brain regions in MDD (Myint et al., 2007; Wichers et al., 2005).”
BackgroundMethodZeden, J.-P., Fusch, G., Holtfreter, B., Schefold, J. C., Reinke, P., Domańska, G., Haas, J., Gruendling, M., Westerholt, A., & Schuett, C. (2010) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1003800213 · Cited by 64
Mind and body: how the health of the body impacts on neuropsychiatry
Renoir, T., Hasebe, K., & Gray, L. J. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00158 · Cited by 72
“…induce activation of the enzyme, indolamine 2, 3 dioxygenase (IDO) in microglia, which metabolizes tryptophan via the kyneurenine pathway (Maes, 1999; Wichers et al., 2005; Dantzer et al., 2008; Maes et al., Frontiers in Pharmacology | Neuropharmacology December 2013 | Volume 4 | Article 158 |…”
BackgroundVeen, C., Myint, A.-M., Burgerhout, K. M., Schwarz, M., Schütze, G. A., Kushner, S. A., Hoogendijk, W. J. G., Drexhage, H. A., & Bergink, V. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.064 · Cited by 63
Maria, N. I., van Helden-Meeuwsen, C. G., Brkić, Z., Paulissen, S. M. J., Steenwijk, E. C., Dalm, V. A. S. H., van Daele, P. L. A., van Hagen, P. M., Kroese, F. G. M., van Roon, J. A. G., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39629 · Cited by 76
“/total (%) Pilocarpine 22/58 (38) 23/66 (35) NS Hydroxychloroquine 21/58 (36) 37/66 (56) NS Fluconazol 6/58 (10) 9/66 (14) NS Corticosteroids 9/58 (16) 7/66 (11) NS”
Schrepf, A., Lutgendorf, S. K., & Pyter, L. M. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.04.010 · Cited by 66
“Spontaneous release of pro-inflammatory cytokines in cultures of primary tumor further suggests that circulating levels of inflammatory molecules are at least partially tumor-derived in some malignancies (Burger et al., 1995; Toutirais et al., 2003; Wigmore et al., 2002).”
Managing Depression during Hepatitis C Treatment
Sockalingam, S., & Abbey, S. E. (2009) · The Canadian Journal of Psychiatry · doi:10.1177/070674370905400906 · Cited by 60
“Animal studies have shown an upregulation of 5-HT transporter messenger ribonucleic acid in response to IFN- ; however, human studies of HCV patients have failed to replicate these findings.48,49 The overlap between the concept of cytokine-induced sickness behaviour, which is defined as anhedonia, anorexia, and decrea…”
BackgroundInfluentialFischer, C. W., Eskelund, A., Budac, D. P., Tillmann, S., Liebenberg, N., Elfving, B., & Wegener, G. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.015 · Cited by 62
Kenis, G., Prickaerts, J., van Os, J., Koek, G. H., Robaeys, G., Steinbusch, H. W. M., & Wichers, M. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000830 · Cited by 58
“As previously reported, total MADRS score significantly increased during treatment (Wichers et al. 2005a).”
BackgroundResultSelf-citationGlucocorticoids and Inflammation: A Double-Headed Sword in Depression?
Horowitz, M. A., Zunszain, P. A., Anacker, C., Musaelyan, K., & Pariante, C. M. (2013) · Modern Trends in Psychiatry · doi:10.1159/000343980 · Cited by 57
Swardfager, W., Herrmann, N., Dowlati, Y., OH, P. I., Kiss, A., Walker, S. E., & Lanctôt, K. L. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.05.019 · Cited by 62
“A more recent study failed to replicate this finding, but not without presenting post hoc analyses implicating an imbalance of kynurenine metabolites further down the degradation pathway (Wichers et al., 2005).”
BackgroundResultBaranyi, A., Meinitzer, A., Stepan, A., Putz-Bankuti, C., Breitenecker, R. J., Stauber, R., Kapfhammer, H.-P., & Rothenhäusler, H.-B. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000348587 · Cited by 56
Toward an Anti-Inflammatory Strategy for Depression
Hayley, S. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00019 · Cited by 56
“…being increased with depression, these kynurenine metabolites (3-hydroxykynurenine and quinolinic acid) have neurotoxic effects and have been reported to synergistically induce free radicals in several neurodegenerative diseases (Wichers and Maes, 2004; Hartai et al., 2005; Wichers et al., 2005).”
Zang, X., Zheng, X., Hou, Y., Hu, M., Wang, H., Bao, X., Zhou, F., Wang, G., & Hao, H. (2018) · The FASEB Journal · doi:10.1096/fj.201700853r · Cited by 59
Ormstad, H., Simonsen, C. S., Broch, L., Maes, M. H. J., Anderson, G., & Celius, E. G. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102533 · Cited by 56
Self-citationAlmulla, A. F., Thipakorn, Y., Vasupanrajit, A., Algon, A. A. A., Tunvirachaisakul, C., Aljanabi, A. A. H., Oxenkrug, G. F., Al‐Hakeim, H. K., & Maes, M. H. J. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100537 · Cited by 96
Self-citationThe role of tryptophan metabolism in postpartum depression
Duan, K., Ma, J., Wang, S., Huang, Z., Zhou, Y., & Yu, H. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-017-0178-y · Cited by 66
“Given the role of pro-inflammatory cytokines in the induction of IDO (Qin et al. 2017; Zhang et al. 2015; Oxenkrug 2011, 2007; Wichers et al. 2005; Wichers and Maes 2004), it is clear that raised levels of immune-inflammatory activity may be intimately linked to the pathophysiology of the PPD.”
BackgroundPancreatic Cancer–Associated Depression: A Case Report and Review of the Literature
Barnes, A., Yeo, T., Leiby, B., Kay, A., & Winter, J. (2018) · Pancreas · doi:10.1097/mpa.0000000000001148 · Cited by 43
Al‐Hakeim, H. K., Abed, A. K., Moustafa, S. R., Almulla, A. F., & Maes, M. H. J. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1194769 · Cited by 60
“Nevertheless, increased kynurenine synthesis produces depressogenic, anxious, excitotoxic, and neurotoxic consequences (Wichers et al., 2005; Maes, 2011a).”
BackgroundSelf-citationNeuroimmune endocrine effects of antidepressants
Carvalho, L. (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s16409 · Cited by 53
Baranyi, A., Meinitzer, A., Breitenecker, R. J., Amouzadeh-Ghadikolai, O., Stauber, R. E., & Rothenhäusler, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137022 · Cited by 58
“[23] examined 16 patients undergoing interferon treatment.”
BackgroundMurakami, Y., Ishibashi, T., Tomita, E., Imamura, Y., Tashiro, T., Watcharanurak, K., Nishikawa, M., Takahashi, Y., Takakura, Y., Mitani, S., et al. (2016) · Scientific Reports · doi:10.1038/srep29920 · Cited by 52
Guloksuz, S., Wichers, M., Kenis, G., Russel, M. G. V. M., Wauters, A., Verkerk, R., Arts, B., & van Os, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060435 · Cited by 52
“It has been argued that IFN-c induced depression is associated with induction of IDO that increases levels of kynurenine (KYN), which in turn leads to formation of neurotoxic metabolites, 3-hydroxykynurenine and quinolinic acid, rather than just TRP degradation by itself [13,39,44,47,48,49].”
BackgroundMethodSelf-citationDahl, J., Andreassen, O. A., Verkerk, R. M., Malt, U. F., Sandvik, L., Brundin, L., & Ormstad, H. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.02.011 · Cited by 54
Self-citationChanges in the immune system in depression and dementia: causal or coincidental effects?
Leonard, B. E., & Myint, A. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.2/bleonard · Cited by 51
Loftis, J. M., Patterson, A. L., Wilhelm, C. J., McNett, H., Morasco, B. J., Huckans, M., Morgan, T., Saperstein, S., Asghar, A., & Hauser, P. (2013) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2012.10.012 · Cited by 50
Epigenetic Mechanisms Shape the Biological Response to Trauma and Risk for PTSD: A Critical Review
Heinzelmann, M., & Gill, J. (2013) · Nursing Research and Practice · doi:10.1155/2013/417010 · Cited by 50
Jiang, X., Xu, L., Tang, L., Liu, F., Chen, Z., Zhang, J., Chen, L., Pang, C., & Yu, X. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1037-9 · Cited by 54
Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer’s Disease
Selles, M. C., Oliveira, M. M., & Ferreira, S. T. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179925 · Cited by 50
Hennings, A., Schwarz, M., Riemer, S., Stapf, T. M., Selberdinger, V. B., & Rief, W. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.09.018 · Cited by 57
Boros, F. A., Bohár, Z., & Vécsei, L. (2018) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2018.03.001 · Cited by 55
Bransfield, R. C. (2018) · Healthcare · doi:10.3390/healthcare6030104 · Cited by 53
Schaefer, M., & Mauss, S. (2008) · Current Drug Abuse Reviews · doi:10.2174/1874473710801020177 · Cited by 53
“roactive metabolites such as 3-hydroxy-kynurenine (3OHKYN) and quinolinic acid (QUIN), has been thought to be associated with central nervous toxicity and the possible pathophysiology of acute and chronic cognitive disturbances [57-60].”
BackgroundMahmoud, M. E., Ihara, F., Fereig, R. M., Nishimura, M., & Nishikawa, Y. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.11.005 · Cited by 50
“Effects of IFN-γ have been linked to depressive symptoms via induction of indoleamine-2, 3-dioxygenase (IDO) activation and tryptophan (Trp) depletion, which results in decreased 5-hydroxytryptamine (5-HT, serotonin) production in the brain [5, 6].”
BackgroundResultInterferon therapy and its association with depressive disorders – A review
Lai, J. Y., Ho, J. X., Kow, A. S. F., Liang, G., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1048592 · Cited by 46
Krause, D., Myint, A.-M., Schuett, C., Musil, R., Dehning, S., Cerovecki, A., Riedel, M. J., Arolt, V., Schwarz, M., & Müller, N. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00016 · Cited by 46
“This finding is in line with hypotheses previously proposed to explain the link between enhanced tryptophan degradation induced by activation of the inflammatory response system and subsequent enhanced formation of neurotoxic QUIN, thereby resulting in clinical symptoms such as depression (23, 32).”
The Psychoimmunology of Lyme/Tick-Borne Diseases and its Association with Neuropsychiatric Symptoms
Bransfield, R. C. (2012) · The Open Neurology Journal · doi:10.2174/1874205x01206010088 · Cited by 54
Cutler, J. A., Rush, A. J., McMahon, F. J., & Laje, G. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111434622 · Cited by 44
Quarantini, L. C., Miranda-Scippa, Â. M. D. A., Schinoni, M. I., Sampaio, A. S., Santos‐Jesus, R., Bressan, R. A., Tatsch, F., de Oliveira, I., & Paraná, R. (2006) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000220824.57769.e5 · Cited by 45
Kulmatycki, K. M., & Jamali, F. (2006) · PubMed · Cited by 55
Lu, D.-Y., Leung, Y.-M., & Su, K.-P. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000338 · Cited by 43
“2001) ; (ii) is associated with alterations in monoamine metabolism and its metabolic enzyme indoleamine 2,3-dioxygenase (IDO) (Capuron et al. 2002b ; Maes et al. 2001; Raison et al. 2009, 2010b ; Wichers et al. 2005) ; and (iii) is associated with alterations in hypothalamic-pituitary-adrenal (HPA) axis function (Cap…”
Background
Metadata
- Authors
- Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M.
- Affiliations
- Maastricht University (NL)
- Maastricht University Medical Centre (NL)
- Ziekenhuis Oost-Limburg (BE)
- University of Antwerp (BE)
- Corresponding author
- Wichers, M C
- Venue
- Molecular Psychiatry
- Published
- 2004-10-19
- Volume
- 10
- Issue
- 6
- Pages
- 538-544
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2078660110
- Cited by
- 445
- References
- 54
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 17 · 2023: 17 · 2022: 15 · 2021: 28 · 2020: 23 · 2019: 17 · 2018: 31 · 2017: 20 · 2016: 30 · 2015: 24 · 2014: 17 · 2013: 26 · 2012: 28
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- indoleamine 2,3-dioxygenase, interferon-alpha, depressive symptoms, tryptophan depletion, kynurenine pathway, kynurenic acid, neurotoxicity, chronic hepatitis C, blood-brain barrier, tryptophan availability, inflammatory cytokines
- MeSH terms
- Adult, Depression, Female, Follow-Up Studies, Humans, Immunotherapy, Kynurenic Acid, Kynurenine, Male, Middle Aged, Psychiatric Status Rating Scales, Tryptophan, Interferon-alpha, Hepatitis C, Chronic, Dioxygenases, Indoleamine-Pyrrole 2,3,-Dioxygenase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.